Gene Modification – Page 2

2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes

8 months ago talkbio0Tagged Administration occupational activities, ambulatory care services, Artificial Intelligence, deal activity, digital health, expansion, Gene Modification, Health care facility, Pharmaceutical Services, regulatory environment, Transplant Registry Unified Management Program

AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

9 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

10 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology

Editas Medicine Undergoes Major Restructuring, Laying Off 65% of Staff Including CMO Amid Failed Search for RENI-CEL Partner

10 months ago talkbio0Tagged Anemia, Sickle Cell, Chronic multifocal osteomyelitis, Editas Medicine, Gene Modification, RENI-CEL, restructuring, Thalassemia

Editas Medicine, layoffs, gene editing, biotech, RENI-CEL, sickle cell disease, thalassaemia, CMO, workforce reduction, restructuring.

Editas Medicine Undergoes Major Restructuring, Cutting 65% of Staff and Halting Sickle Cell Therapy Development

10 months ago talkbio0Tagged Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Editas Medicine, Gene Modification, Industry, restructuring, sickle

Editas Medicine, layoffs, restructuring, sickle cell therapy, CRISPR gene editing, biotech industry

Revolutionizing AATD Treatment: Emerging Therapies to Replace Augmentation Therapy

12 months ago talkbio0Tagged alpha 1-Antitrypsin Deficiency, Alpha-1, Antitrypsin Deficiency, augmentation therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hereditary Diseases, RNA Interference

Alpha-1 Antitrypsin Deficiency (AATD), Genetic Disorder, New Therapies, Augmentation Therapy, RNA Interference (RNAi), Gene Editing, CRISPR

Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study

12 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Functional, Gene Modification, Intellia, NTLA-2002, Phase 2 Clinical Trials, Swelling attacks

CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure

Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks

12 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Infrequent, Intellia

Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases

Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus

1 year ago talkbio0Tagged BMS, Burning Mouth Syndrome, Cell Therapy, Edit, ex vivo, Gene Modification, Ifosfamide/Methotrexate/Procarbazine protocol, PASSIGE, pipeline, Prime Medicine, Reprioritization, squibb, strategic collaboration, Technology

Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration

Tome Biosciences, a High-Profile Gene Editing Startup, Announces Massive Layoffs and Sale Plans

1 year ago talkbio0Tagged financial struggles, Gene Modification, startup, Tome Biosciences

Tome Biosciences, gene editing, layoffs, startup, biotech, financial struggles